Immune checkpoint blockers, including anti-cytotoxic T lymphocyte-associated protein (CTLA)-4 and anti-PD1/PD-L1, have been approved by the U.S. Food and Drug Administration (FDA) and are used for the treatment of melanoma and non-small-cell lung carcinoma (NSCLC) [97]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.